Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: A retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials

This publication has 31 references indexed in Scilit:

• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
  The Lancet, 2003
• National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
  Annals of Internal Medicine, 2003
• Predictors of the Development of Hyperkalemia in Patients Using Angiotensin-Converting Enzyme Inhibitors
  American Journal of Nephrology, 2000
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
  New England Journal of Medicine, 1999
• Tolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction
  American Heart Journal, 1994
• Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions
  New England Journal of Medicine, 1992
• Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
  New England Journal of Medicine, 1991
• Studies of Left Ventricular Dysfunction (SOLVD)—Rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction
  The American Journal of Cardiology, 1990
• Effects of Enalapril on Mortality in Severe Congestive Heart Failure
  New England Journal of Medicine, 1987
• Prediction of Creatinine Clearance from Serum Creatinine
  Nephron, 1976